alexa Method Development and Validation for Desogestrel and Ethinylestradiol in Combined Pharmaceutical Dosage Form by RP-HPLC | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Method Development and Validation for Desogestrel and Ethinylestradiol in Combined Pharmaceutical Dosage Form by RP-HPLC

Sanjay Bais1*, Anil Chandewar2, Imran Popte2, Indrajeet Singhvi3 and Khemchand Gupta3

1Research Scholar, PRIST University, Thanjavur-Tamilnadu, India

2P Wadhwani College of Pharmacy, Yavatmal-MS, India

3Pacific College of Pharmacy, Udaipur, Rajasthan, India

*Corresponding Author:
Sanjay Bais
Research Scholar, PRIST University
Thanjavur-Tamilnadu, India
E-mail: [email protected]

Received date: March 01, 2013; Accepted date: July 15, 2013; Published date: August 13, 2013

Citation: Bais S, Chandewar A, Popte I, Singhvi I, Gupta K (2013) Method Development and Validation for Desogestrel and Ethinylestradiol in Combined Pharmaceutical Dosage Form by RP-HPLC. Pharm Anal Acta 4:262. doi:10.4172/2153-2435.1000262

Copyright: © 2013 Bais S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta

Keywords

Desogestrel; Ethinyloestradiol; Reversed-phase HPLC; Validation

Introduction

Desogestrel is chemically, 13-Ethyl-11-methylidene-18, 19-dinor- 17α-pregn-4-en-20-yn-17-ol having Molecular Formula and Molecular Weight C22H30O and 310.5 respectively. It is white to offwhite, crystalline solid with a pKa of 13.04, slightly soluble in acetone and ethanol (95%) It belongs to Contraceptives category [1].

Ethinyloestradiol Chemically is 19-Nor-17α-pregna-1, 3, 5(10)-trien-20-yne-3, 17-diol having Molecular Formula and Molecular weight C20H24O2 and 296.40 respectively. It is White crystalline powder, freely soluble in alcohol; with pKa 17.59.It also belongs to Contraceptives category. It is mainly used in hormone therapies for androgen dependent disorders, acne, hirsutism, seborrhea. Recently it is shown that, the continuous daily ovarian activity and eliminate cyclic fluctuations in estradiol [2,3], progesterone, luteinizing hormone and follicle-stimulating hormone [4]. In addition, the combination of these drugs was used as an oral contraceptive for female patients with androgenic symptoms [2]. In the present research the attempt has been made to use two detector linearly for both drugs (Figure 1).

pharmaceutica-analytica-acta-Desogestrel

Figure 1a: Structure of Desogestrel.

pharmaceutica-analytica-acta-Ethinylestradiol

Figure 1b: Structure of Ethinylestradiol.

Literature survey reveals that several methods were reported for estimation of like HPLC [3-11], RPHPLC [12,13]. Derivative spectrophotmetry [14], LC [15], HPLC-MS [16,17] Colorimetry [18].

Experimental Work

Instrumentation

The HPLC of Waters Alliance ID:-FCLS/Q/78 Detector UV 2487 and Fluorescence 2475 was used .The pH Meter, pH Tutor, Cyber Scan, Balance Sartorious & Mettler Toledo UV-Visible Spectrophotometer, Varian Single beam were other equipments used during the research work.

Determination of wavelength maxima and calibration curve by using ultraviolet visible spectroscopy

Stock Solution of Ethinyloestradiol: Accurately weighed quantity (3.75 mg) of Ethinylestradiol was transferred to 50.0 ml volumetric flask, 30 ml of diluent was added and sonicated to dissolve the drug and diluted up to the mark with diluent (Concentration 125 mcg/ml).

Desogestrel stock standard solution:

Stock solution of desogestrel: Accurately weighed quantity (15 mg) of Desogestrel was transferred to 20 ml volumetric flask, 5 ml of diluent was added and sonicated to dissolve the drug .About 2 ml of Ethinylestradiol stock solution was added and mix well, diluted up to the mark with diluent. (Conc. of Desogestrel is about 6000 mcg/ml, conc. of Ethinyloestradiol is about 125 mcg/ml).

Determination of wavelength maxima for Ethinylestradiol

The aliquot portions of stock standard solutions of Ethinylestradiol were diluted appropriately with solvent to obtain concentration 20 μg/mL of drug. The solutions were scanned in the range of 400- 200 nm in 1 cm cell against blank. The UV absorbance spectrum of and Ethinyloestradiol is shown in Figure 2. From the spectrum the wavelengths selected for estimation of Ethinylestradiol were 210 nm and 275 nm.

pharmaceutica-analytica-acta-Spectra-Ethinylestradiol

Figure 2: Spectra of Ethinyloestradiol.

Determination of wavelength maxima for Desogestrel

The aliquot portions of stock standard solutions of Desogestrel were diluted appropriately with solvent to obtain concentration 20 μg/mL of drug. The solutions were scanned in the range of 400 -200 nm in 1 cm cell against blank. The UV absorbance spectrum of and Desogestrel is shown in Figure 3. From the spectrum the wavelengths selected for estimation of Desogestrel were 210 nm and 275nm.

pharmaceutica-analytica-acta-Spectra-Desogestrel

Figure 3: Spectra of Desogestrel.

Study of Beer- Lambert law

The aliquot portions of stock standard solutions of Desogestrel and Ethinyloestradiol were diluted appropriately with solvent to get a series of concentration between 5-50 (μg/ml) of Desogestrel and Ethinyloestradiol. Similarly aliquot portions of stock standard solutions were mixed and diluted to get series of concentration between 5-50 μg/ml. The absorbance of each solution was measured at 275 nm and absorbance of Ethinyloestradiol only was measured 275 nm in 1 cm cell against solvent blank. The graphs plotted as concentration Vs absorbance at selected wavelengths are shown in Figure 4 and 5.

pharmaceutica-analytica-acta-Beer-Lambert-law

Figure 4: Plot of Beer-Lambert law forEthinyloestradiol at 275 nm.

pharmaceutica-analytica-acta-Beer-Lambert

Figure 5: Plot of Beer-Lambert law for Desogestrel at 210 nm.

Selection of common solvent (Diluent): HPLC grade water and Acetonitrile of analytical reagent grade in the ratio of 50:50 v/v was selected as common solvent for developing Spectral characteristics of drug. The selection was made after assessing the solubility of both the drugs in different solvents.

Preparation of standard stock solution:

Stock Solution A: Accurately weighed 30.0 mg of Desogestrel working standard accurately weighed and was transferred to 100.00 ml volumetric flask, 70 ml of acetonitrile was added and sonicated till the material completely dissolve. The volume was made with Acetonitrile and shaken. The 5.00 ml of resulting solution was transferred to 100.00 ml volumetric flask, to volume was made with diluents.

Stock Solution B: About 30.0 mg of Ethinyloestradiol working standard accurately weighed and was transferred to 100.00 ml volumetric flask, about 70 ml of acetonitrile was added and sonicated till the material was completely dissolved. The volume was made up to mark with Acetonitrile and shaken. The 5 ml of resulting solution was transferred to 100.00 ml volumetric flask. The final volume was made by using diluents (Figure 6).

pharmaceutica-analytica-acta-Standard-stock

Figure 6: Chromatogram of Standard stock solution (UV detector).

Selection of chromatographic condition for estimation of drugs

In this method development and validation for Desogestrel and Ethinylestradiol mixture. The detection of Desogestrel was done by using UV detector and Ethinyloestradiol was done on fluorescence detector. The detection of both drug was not possible on same detector because Ethinyloestradiol quantity in the formulation was very less and it does not shows any peak on U.V. detector, that’s why we had used fluorescence detector for Ethinyloestradiol detection which is linearly arranged with U.V. detector.

Selection of mobile phase

Standard stock solution A and B were appropriately diluted with diluents to obtain final concentration of Desogestrel and Ethinylestradiol, respectively. The standard solutions were injected into the HPLC system and run in different solvent systems. Mixture of different solvents were tried in order to determine optimum chromatographic conditions for effective separation of Desogestrel and Ethinyloestradiol. After several permutation and combination, it was found that mixture of Buffer, 0.01 M potassium dihydrogen phosphate buffer and Acetonitrile (50:50) gives satisfactory results as compared to other mobile phases. Finally, the optimal composition of the mobile phase, Buffer: Acetonitrile (50:50 v/v), and flow rate 2.0 ml/min showed good resolution, peak shape and desired elution. Retention time of Desogestrel was 13.9 min and that of Ethinylestradiol was 2.4 min.

Preparation of mobile phase

The 500 ml of potassium dihydrogen phosphate buffer and 500 ml of acetonitrile was mixed in 1000 ml glass bottle and filtered through 0.45 μm membrane filter and degassed before use.

Selection of analytical wavelength

Standard stock solution A and B were injected separately to obtain extracted Chromatogram of Desogestrel and Ethinylestradiol. Each solution was scanned using PDA detector system and their Spectra were obtained. The wavelength selected was 210 nm as both the drugs showed significant absorbance at this wavelength.

Optimized chromatographic conditions

• Detector: Fluorescence detector for Ethinyloestradiol UV detector for Desogestrel

• Wavelength: 310 nm Emission and 285 nm excitation for Ethinylestradiol 210 nm for Desogestrel

• Column: Zorbax SB Phenyl C18 column (4.6 x 150 mm).

• Flow Rate: 2.0 ml / minute

• Injection volume: 200 μl

• Run time: 20 minutes

• Retention Time: Ethinyloestradiol about 2.4 minute : Desogestrel about 13.9 minute

• Run Time: 20.0 min.

• Column Oven Temp: Ambient

• Sample Cooler Temp: Ambient

Validation Program

System suitability

Prepare the system suitability solution as per the proposed test method and inject into the HPLC system by following the instrumental condition as per the test method. Record the system suitability parameters observed into the following (Table 1) [19].

  Peak Name RT (min) Area (µV*sec) USP Tailing
1 Desogestrel 13.510 75432 1.18
2 Ethinyloestradiol 2.445 469650 1.46

Table 1: System suitability studies.

Precision studies

System precision: The standard solution was prepared as per test method and injected into the HPLC system in five replicates. The % RSD was evaluated and the observations (Table 2).

Injection No. Area Response
Desogestrel Ethinyloestradiol
1 75432 469650
2 76564 468650
3 76188 474215
4 76282 485100
5 75821 486150
Average 76058 476753
SD 76496.48 485127.5
% RSD 0.6 1.8

Table 2: System precision studies.

Method precision: Six assay sample preparations from a single lot of Desogestrel and Ethinyloestradiol Tablets USP (0.15 mg / 0.03 mg) were made and analysed as per methodology. Content of Desogestrel and Ethinylestradiol in Desogestrel and Ethinylestradiol Tablets USP were calculated. L1 (Maximum allowed acceptance value) of Desogestrel and Ethinylestradiol in assay percentage of Desogestrel and Ethinylestradiol in six assay sample preparations was calculated and found within acceptance criteria. Analytical method meets the acceptance criteria for Method Precision. Hence, the method is precise (Table 3 and 4).

Injection No. Area Response
Desogestrel Ethinyloestradiol
1 73829 447030
2 73723 447540
3 73809 447890
4 73629 447010
5 73525 447639
6 73660 447271
Average 73810 447400
SD 113.6981 318.3452
% RSD 0.15 0.071

Table 3: Method precision area.

Observation No. Assay of Desogestrel (%) Assay of Ethinyloestradiol (%)
1. 99.3 99.5
2. 99.5 99.2
3. 99.7 99.7
4. 99.3 101.1
5. 99.3 100.6
6. 98.7 101.6
Assay 99.3 100.3
Minimum 98.7 99.2
Maximum 99.7 101.6
% RSD 0.3 0.9

Table 4: Method precision data.

Ruggedness (Intermediate precision): Ruggedness of method was verified by preparing two sets of content uniformity test preparation and six assay sample preparations from a single lot of Desogestrel and Ethinyloestradiol Tablets USP (0.15 mg/0.03 mg) and analysed as per methodology by different analyst, by using different instrument (HPLC), different column, and different make of reagent and on a different day. Percentage of impurities was calculated. Content of Desogestrel and Ethinyloestradiol in Desogestrel and Ethinyloestradiol Tablets USP were calculated. Assay percentage of Desogestrel and Ethinyloestradiol in six assay sample preparations of Method Precision and Intermediate Precision was calculated and found within acceptance criteria as given in Table 5 and 6. Analytical method meets the acceptance criteria for Intermediate Precision (Ruggedness). Hence, method is precise and rugged.

Observation No.  Assay of Desogestrel (%) SET I Assay of Desogestrel (%) SET II
1. 99.3 98.9
2. 99.5 99.4
3. 99.7 98.5
4. 99.3 98.7
5. 99.3 98.6
6. 98.7 99.7
Assay 99.3 99.0
Minimum 98.7 98.5
Maximum 99.7 99.7
% RSD 0.3 0.5
Overall % RSD of results (N = 12) of two different sets 0.4
  Ethinyloestradiol SET I SET II
1. 99.5 100.4
2. 99.2 99.5
3. 99.7 99.3
4. 101.1 101.5
5. 100.6 99.7
6. 101.6 99.9
Assay 100.3 100.1
Minimum 99.2 99.3
Maximum 101.6 101.5
% RSD 0.9 0.8
Overall % RSD of results (N = 12) of two different sets 0.9

Table 5: Comparison between method precision and intermediate precision.

Level Desogestrel Ethinyl Estradiol
Concentration (mg/mL) Average Area response Concentration (mg/mL) Average Area response
50 0.3064 38983 0.06036 227772
75 0.4596 57156 0.09054 329650
100 0.6128 77449 0.12072 459720
125 0.7660 97777 0.15090 571145
150 0.9192 115030 0.18108 685265
200 1.2256 151600 0.24144 904195
Slope 123215 3769899
Intercept 1575.5 -1328.1
Correlation coefficient (r) 1.000 1.000

Table 6: Linearity of detector response.

Study of linearity and range

Preparation of stock solution and linearity level of Desogestrel: The 1500 mg of working standard of Desogestrel transferred in 50 ml of volumetric flask and diluted with 30 ml of diluent and sonicated to dissolve, volume was made with diluent. From above solution linearity level of 10-150% for Desogestrel were prepared. (Conc. of Desogestrel 30000 mcg/ml) as given in (Figure 7).

pharmaceutica-analytica-acta-Linearity-graph

Figure 7: Linearity graph for Desogestrel.

Preparation of stock solution and linearity level of Ethinyloestradiol: 75 mg of working standard of Ethinylestradiol was transferred in 200 ml of volumetric flask and dilute with 100 ml of diluent and sonicated to dissolve, make up the volume with diluent. From above solution linearity level of 10-150% for Ethinyloestradiol were prepared. (Conc. of Ethinyloestradiol 375 mcg/ml) Then each solution (20 μL) was injected into the column and chromatographed using optimized chromatographic conditions. The corresponding chromatograms were recorded and area of each peaks for Desogestrel and Ethinyloestradiol were measured at 210.0 nm. Each sample solution was chromatographed in triplicate and the mean peak area for Desogestrel and Ethinyloestradiol was calculated (Figure 8).

pharmaceutica-analytica-acta-Linearity-Ethinyloestradiol

Figure 8: Linearity graph for Ethinyloestradiol.

Specificity

Placebo interference study: Prepared the placebo solution by weighing equivalent amount of placebo present in the sample to be taken for assay preparation in triplicate, diluted it as per the test method and injected into the HPLC system. Evaluate the % interference from placebo and recorded the observation as given in Table 7.

Sr. No. Desogestrel Ethinyloestradiol
Assay (mg) Assay % of LC Assay (mg) Assay % of LC
1 74.41 99.2 0.783 104.5
2 74.72 99.6 0.798 106.5
3 74.62 99.7 0.789 105.2
Average 74.6 99.5 0.790 105.4
SD 0.1582 0.2646 0.0075 0.8544
% RSD 0.2 0.3 1.0 0.8

Table 7: Results and statistical data for estimation of DESO and ETHY in marketed formulation.

Accuracy

The accuracy of method was determined by recovery experiments. The recovery studies were carried out using standard addition method at 50, 100 and 150% level; known amount of standards was added to reanalyzed sample and subjected them to the proposed HPLC method. Percentage recovery was calculated from the amount found and actual amount added result shows in Table 8 and 9.

Recovery level Desogestrel With Placebo
Amount added (mcg / ppm) Amount recovered (mcg / ppm) % Recovery Average recovery % RSD
70% 0.4168 0.4220 101.2 101.3 0.3
0.4168 0.4235 101.6
0.4168 0.4208 101.0
100% 0.5954 0.6041 101.5 100.8 0.6
0.5954 0.6002 100.8
0.5954 0.5963 100.2
130% 0.7740 0.7718 99.7 99.7 0.1
0.7740 0.7719 99.7
0.7740 0.7728 99.8
Overall 100.6 0.33

Table 8: Recovery data for desogestrel.

Recovery level Ethinyloestradiol With Placebo
Amount added (mg / ppm) Amount recovered (mg / ppm) % Recovery Average recovery % RSD
70% 0.0835 0.0831 99.5 99.7 0.4
0.0835 0.0836 100.1
0.0835 0.0830 99.4
100% 0.1192 0.1209 101.4 101.5 0.2
0.1192 0.1210 101.5
0.1192 0.1212 101.7
130% 0.1550 0.1562 100.8 101.2 0.3
0.1550 0.1568 101.2
0.1550 0.1573 101.5
Overall 100.8 0.33

Table 9: Recovery data for Ethinyloestradiol.

Standard stock solution (for Ethinyloestradiol): Accurately 37.5 mg of Ethinyloestradiol WS was weighed and transferred into a 50 ml volumetric flask, add 30 ml of diluent and sonicated to dissolve, then diluted up to the mark with diluent and mixed well. Then make it up to the mark with diluent.

Mixed standard preparation: Weigh accurately 150 mg of Desogestrel working standard into a 20 ml volumetric flask, add 5 ml of diluent and sonicate to dissolve. The Ethinyloestradiol 2 ml stock solution was added and mixed well. The volume was made up to the mark with diluent.

Sample preparation

Accuracy: The samples were prepared by adding active ingredients into the placebo at different concentrations or spiking the solution on placebo (50%, 100%, and 150%) each in triplicate. Injected each preparation into the HPLC system.

Procedure: The standard preparation and sample preparations were injected for recovery solutions into the chromatograph and the peak responses were measured for the major peaks. The system suitability was checked and the results were recorded.

Application of Proposed Method for Estimation of Desogestrel and Ethinylestradiol on Marketed Tablet Formulation

Test preparation

The 20 tablets was weighed and transferred to 200.00 ml volumetric flask, 120 ml of diluents was added, the stopper was inserted and sonicated with intermittent shaking for 30 minutes. Volume was made with diluent and shaken. A portion of this solution was centrifuged at 3000 RPM for 10 minutes. 2.00 ml of resulting solution was transferred to 50.00 ml volumetric flask; the volume was made with diluent and shake. Such two sample preparation was prepared. (Desogestrel 0.6 mcg/ml and Ethinyloestradiol 0.12 mcg/ml) as given in Table 8 and 9.

Procedure and system suitability for content uniformity test

The column was equilibrated with the mobile phase with chromatographic condition for the proper baseline. First injected diluent as blank (one injection). Then injected standard preparation-I (one injection) and checked the system suitability parameter as given below (A). Then standard preparation-II was injected (one injection) and checks the similarity factor as given below (B). After getting the satisfactory result, standard preparation-II was injected (four injections), check relative standard deviation of five replicate injections of standard preparation-II as given below (C), diluents was injected as blank (one injection). Then proceed for duplicate injections of assay test preparation but inject one injection of standard preparation-II as bracketing standard after each five injections of test preparation and check the relative standard deviation as given below (D).

A. Tailing factor for Desogestrel and Ethinyloestradiol should Not be more than 2.0

B. Similarity factor between area of standard preparation-I and standard preparation-II should be 0.98 to 1.02

image

C. Relative standard deviation of 5 replicate injections of standard preparation-II should Not be more than 2.0%

D. Relative standard deviation between 5 replicate injections and bracketing standards should Not be more than 2.0%

Conclusion

From the studies it can be concluded that RP-HPLC technique can be successfully used for the estimation of Desogestrel and Ethinylestradiol in their combined dosage Tablet formulations. The method shows good reproducibility compared to UV-spectrophotometric methods. The RP-HPLC method is accurate, precise, specific, reproducible and sensitive. No interference of additives, matrix etc. is encountered in these methods. Further studies on other pharmaceutical formulations would throw more light on these studies. The methods were found to be sensitive, reliable, reproducible, rapid and economic also.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 7th International Conference on Phamaceutical Auditing
    June 08-09, 2018 Baltimore, USA
  • 4th International Conference on Drug Discovery, Designing and Development
    June 27-28, 2018 Vancouver, Canada
  • 18th World Pharma Congress
    October 18-19, 2018 Warsaw, Poland

Article Usage

  • Total views: 12679
  • [From(publication date):
    July-2013 - May 28, 2018]
  • Breakdown by view type
  • HTML page views : 8785
  • PDF downloads : 3894
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7